# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price tar...
Citigroup analyst David Lebovitz maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target fro...
JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and lower...
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(7.38) per share which missed the analyst consensus estima...
B of A Securities analyst Alexandria Hammond initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Underperfor...
Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the pri...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalco...